Measuring Tumor Succinate and Fumarate to Resolve Pathogenicity of an SDHA Variant

Clin Chem. 2021 Mar 31;67(4):696-699. doi: 10.1093/clinchem/hvab004.

Dahlia F Davidoff^{1

2

3}, Catherine Luxford^{1

2}, Edward Kim^{1

2}, Talia Novos⁴, Andrea R Horvath⁴, Anthony J Gill^{2

5}, Trisha Dwight^{1

2}, Roderick J Clifton-Bligh^{1

2

3}, John R Burgess^{6

7}

¹ Cancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital, St Leonards, NSW, Australia.
² University of Sydney, Sydney, Australia.
³ Department of Endocrinology, Royal North Shore Hospital, St Leonards, NSW, Australia.
⁴ Department of Chemical Pathology, NSW Health Pathology, Prince of Wales Hospital, Randwick, NSW, Australia.
⁵ Cancer Diagnosis and Pathology Group, Kolling Institute, Royal North Shore Hospital, St Leonards, NSW, Australia.
⁶ Department of Diabetes and Endocrinology, Royal Hobart Hospital, Hobart, TAS, Australia.
⁷ School of Medicine, University of Tasmania, Hobart, TAS, Australia.

No abstract available

Keywords: SDHA; mass spectrometry; paraganglioma; pheochromocytoma; succinate dehydrogenase.

Grants and funding